Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vamorolone in Children With Mild-Moderately Active Ulcerative Colitis
NCT04348890Phase 2Withdrawn
- Sponsor
- ReveraGen BioPharma
- Start
- Sep 2020
- Primary completion
- Sep 2022
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, open-label, single-arm trial of vamorolone in ulcerative colitis (UC), sponsored by ReveraGen BioPharma. Primary endpoint: Clinical Remission at 8 weeks. Planned start Sep 2020; status: withdrawn.
02
Drugs
vamorolone
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04348890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04348890.